Gujarat Themis Biosyn Ltd

Shares of Gujarat Themis Biosyn Ltd declined sharply on 23 Jan 2026, hitting an intraday low of Rs 316.3, reflecting significant price pressure amid a broadly negative market environment and heightened volatility.

Gujarat Themis Biosyn Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite a strong daily price gain of 6.96%, the stock’s technical indicators present a complex picture, with mixed signals across weekly and monthly timeframes, prompting a downgrade in its Mojo Grade from Hold to Sell as of 21 January 2026.

Gujarat Themis Biosyn Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 21 January 2026. This shift reflects a combination of deteriorating technical indicators, expensive valuation metrics, flat financial trends, and subdued quality scores, signalling caution for investors amid a challenging market environment.

Gujarat Themis Biosyn Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent downgrade in daily price performance, the stock’s long-term fundamentals continue to show resilience, prompting a reassessment of its market positioning and technical outlook.

Shares of Gujarat Themis Biosyn Ltd declined sharply on 20 Jan 2026, touching an intraday low of Rs 332.2, reflecting a significant price pressure of -7.88% amid broader market weakness and sector underperformance.

Gujarat Themis Biosyn Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced shift in its technical outlook and valuation metrics despite flat recent financial performance. The upgrade, effective from 19 January 2026, is driven primarily by improved technical indicators and a reassessment of the company’s quality and valuation parameters within the Pharmaceuticals & Biotechnology sector.

Gujarat Themis Biosyn Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has recently exhibited a shift in price momentum, moving from a sideways trend to a mildly bullish stance. This change is underscored by a complex interplay of technical indicators, including MACD, RSI, moving averages, and Bollinger Bands, signalling a nuanced outlook for investors as the stock attempts to regain upward momentum amid mixed signals.

Gujarat Themis Biosyn Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 11 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 January 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Gujarat Themis Biosyn Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 11 Nov 2025. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 30 December 2025, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Gujarat Themis Biosyn Ltd has experienced a nuanced shift in its technical momentum, with key indicators signalling a transition from a strongly bullish stance to a more cautiously optimistic outlook. Despite a modest day gain of 0.37%, the stock’s technical parameters reveal a complex interplay of bullish and bearish signals, prompting a reassessment of its near-term trajectory within the Pharmaceuticals & Biotechnology sector.

Gujarat Themis Biosyn, a key player in the Pharmaceuticals & Biotechnology sector, has demonstrated a notable shift in price momentum and technical indicators, signalling a bullish phase in its market trajectory. Recent evaluation adjustments highlight a transition in technical trends, with moving averages and Bollinger Bands supporting an optimistic outlook despite mixed signals from momentum oscillators.

Gujarat Themis Biosyn recorded a robust intraday performance today, reaching a high of Rs 441.15, reflecting a 7.76% rise. This surge outpaced the Pharmaceuticals & Biotechnology sector and the broader market, underscoring notable trading momentum in the stock.

Guj. Themis Bio., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting a nuanced shift in its financial and technical outlook. This adjustment follows a detailed reassessment of the company’s quality, valuation, financial trends, and technical indicators, highlighting both strengths and challenges in its recent performance.

Guj. Themis Bio., a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting shifts in key analytical parameters. This adjustment highlights evolving perspectives on the company’s valuation, financial trends, quality metrics, and technical outlook amid a backdrop of mixed performance indicators.

Gujarat Themis Biosyn, a notable player in the Pharmaceuticals & Biotechnology sector, has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across various timeframes. Recent market data reveals a mild adjustment in the company’s technical parameters, coinciding with a day change of -3.73% and a current price of ₹420.75, down from the previous close of ₹437.05.

Gujarat Themis Biosyn has reported significant financial improvements for the quarter ending September 2025, achieving record net sales of Rs 42.35 crore and a PBDIT of Rs 20.95 crore. The company also demonstrated strong operational efficiency with a 49.47% operating profit margin and impressive profitability metrics.